Literature DB >> 33337396

Bolus versus continuous feedings following treatment for medical necrotizing enterocolitis.

M L Reppucci1, M Paul2, P Khetan1, B A Coakley1,3.   

Abstract

BACKGROUND: Necrotizing enterocolitis (NEC) is a serious, often fatal, disease of neonates. Minimal data exists regarding the optimal method for reintroducing feeds after successful treatment. This study aims to compare outcomes in patients reintroduced to bolus or continuous feeds after treatment for medical NEC.
METHODS: A retrospective review of infants treated for medical NEC in the neonatal intensive care unit (NICU) from 2011-2018 was performed. Demographics, information about initial feeds, clinical diagnosis data, and information about reintroduction of feeds were recorded. Patients with significant congenital heart disease or those who required procedures for treatment were excluded.
RESULTS: Sixty-one patients were analyzed; 45 were reintroduced to bolus feeds and 16 to continuous feeds. There were no differences between the two groups. Bolus-fed patients reached goal feeds quicker (p = 0.007), required fewer days of parenteral nutrition (p = 0.002), had shorter hospital stays (p = 0.013) and were discharged faster from diagnosis to discharge (p = 0.002). Differences were confirmed with multivariate regression.
CONCLUSION: Infants given bolus feeds reached goal feeds faster, required less time on PN, and were discharged quicker than those fed continuously. This suggests that, compared to continuous feeding, bolus feeding is associated with superior clinical outcomes among patients treated for medical NEC.

Entities:  

Keywords:  Necrotizing enterocolitis; feedingzzm321990

Mesh:

Year:  2021        PMID: 33337396     DOI: 10.3233/NPM-200584

Source DB:  PubMed          Journal:  J Neonatal Perinatal Med        ISSN: 1878-4429


  1 in total

1.  Comparison of Necrotizing Enterocolitis in Pre-mature Infants vs. Term-Born Infants With Congenital Heart Disease.

Authors:  Gabriela Frid; Marina Reppucci; Tony Lum; Megan Paul; Howard Seiden; Brian A Coakley
Journal:  Front Pediatr       Date:  2021-12-20       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.